Experts of Baikal Communications Group — Valery Afanasyev, Head of the Government Relations and Regulatory Risk Assessment Practice, and Zhanna Logacheva, Expert of the same practice — have prepared an analytical overview of the transformation of the regulatory framework governing the dietary supplements (biologically active additives, BAA) market in Russia in 2025. The publication was released on the Retail.ru platform and focuses on the key legislative changes and their impact on the industry.

According to DSM Group, by September 2025 the Russian dietary supplements market reached RUB 129.8 billion, demonstrating nearly 25% year-on-year growth. The rapid expansion of this segment has driven the need for stronger state control over the circulation of illegal products. Since 2023, a mandatory product labeling system for dietary supplements has been introduced, and further measures aimed at tightening regulatory oversight over manufacturers are under development. In addition, starting in October 2026, the Law on the Platform Economy will come into force, obliging marketplaces to prevent the sale of unregistered dietary supplements.

The key regulatory milestone of the year was the entry into force of Federal Law No. 150-FZ dated June 7, 2025, which legally authorized physicians to prescribe dietary supplements when medically indicated, and also introduced restrictions on interactions between healthcare professionals and supplement manufacturers. In order to implement this law, the Russian Ministry of Health is currently developing quality and efficacy criteria for dietary supplements, which are scheduled to take effect on March 1, 2026.

Experts note that the state is shifting from selective supervision to comprehensive regulation of the market, gradually aligning dietary supplement requirements with certain pharmaceutical standards. This is expected to enhance industry transparency and strengthen consumer confidence, while simultaneously increasing the regulatory burden on manufacturers.

“Including dietary supplements in clinical recommendations will expand the consumer base and strengthen public trust. However, there is a risk of excessive regulation. The requirement to reference active ingredients in dietary supplements solely within Russian clinical guidelines appears overly stringent, given the lack of consensus on the efficacy of many nutraceuticals. This may result in the withdrawal of beneficial products from the market. Assessing dietary supplements according to criteria applicable to medicinal products distorts the nature of the category and hampers innovation. What is needed is flexible regulation that encourages product diversity and meets consumers’ healthcare needs,” explained Zhanna Logacheva, Expert at the Government Relations and Regulatory Risk Assessment Practice.

The full version of the article is available on Retail.ru

Back to news